Related Experiment Video
Updated: Aug 14, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation
Anja Kordowski1, Monica Pomaville2, Jessica B Foster2,3
1Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Abstract:
Diffuse midline glioma, H3K27-altered (DMG) is a group of central nervous system (CNS) tumors with no curative treatment options. First described in the early 20th century, prognosis and clinical outcome for patients have changed very little, and the only standard treatment modality remains radiation therapy. The development of targeted therapies against DMG has long been hindered due to the paucity of tumor tissue and disease models for laboratory research. However, access to patient-derived tumor tissue and the subsequent establishment of DMG preclinical models in recent years has led to a deeper understanding of underlying disease mechanisms and aided the development of novel therapeutic agents. Here, we provide an overview of newly established DMG modeling systems in the preclinical setting leading toward immunotherapy clinical trials for patients with DMG.
Insights
Diffuse midline glioma (DMG) research is advancing with new preclinical models. These models offer hope for developing targeted therapies and advancing immunotherapy clinical trials for this challenging CNS tumor.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Immunotherapy
Background:
- Diffuse midline glioma, H3K27-altered (DMG) represents a significant challenge in central nervous system (CNS) oncology.
- Current treatment options, primarily radiation therapy, offer limited efficacy, with little improvement in patient prognosis over decades.
Purpose of the Study:
- To review recent advancements in Diffuse midline glioma (DMG) modeling systems.
- To highlight the transition from preclinical models to immunotherapy clinical trials for DMG patients.
Main Methods:
- Review of established Diffuse midline glioma (DMG) preclinical models.
- Analysis of the impact of these models on understanding DMG biology and therapeutic development.
Main Results:
- Recent establishment of patient-derived Diffuse midline glioma (DMG) models has significantly improved research capabilities.
- These models facilitate a deeper understanding of DMG pathogenesis and the development of novel therapeutic strategies.
Conclusions:
- Newly developed Diffuse midline glioma (DMG) preclinical models are crucial for advancing treatment strategies.
- These models pave the way for immunotherapy clinical trials, offering new hope for patients with Diffuse midline glioma (DMG).
